Abstract: Cancer-associated venous thromboembolism (CAVTE) is a common complication and cause of death in cancer patients.The high risks for VTE recurrence and severe bleeding after the cessation of anticoagulation therapy may lead to delayed treatment and increased mortality.Current guidelines at home and abroad do not recommend direct primary prevention; instead, they recommend the assessment of the risk of VTE in each patient before chemotherapy.In recent years, scholars have been committed to developing accurate prediction tools for the risk assessment of VTE in cancer patients.In this paper, we review the current studies on bleeding and recurrence risks associated with CAVTE after anticoagulation therapy, guidelines for the prevention and treatment of VTE, and risk assessment models for VTE.